Institute for Cancer Genetics.
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York 10032, USA.
Cold Spring Harb Perspect Med. 2021 May 3;11(5):a035402. doi: 10.1101/cshperspect.a035402.
Peripheral T-cell lymphomas (PTCLs) constitute a highly heterogeneous group of hematological diseases with complex clinical and molecular features consistent with the diversity of the T-cell type from which they originate. In the past several years, the systematic implementation of high-throughput genomic technologies for the analysis of T-cell malignancies has supported an exponential progress in our understanding of the genetic drivers of oncogenesis and unraveled the molecular complexity of these diseases. Recent findings have helped redefine the classification of T-cell malignancies and provided novel biomarkers to improve diagnosis accuracy and analyze the response to therapy. In addition, multiple novel targeted therapies including small-molecule inhibitors, antibody-based approaches, and immunotherapy have shown promising results in early clinical analysis and have the potential to completely change the way T-cell malignancies have been treated traditionally.
外周 T 细胞淋巴瘤（PTCLs）是一组高度异质性的血液系统疾病，具有复杂的临床和分子特征，与它们起源的 T 细胞类型的多样性一致。在过去的几年中，高通量基因组技术在 T 细胞恶性肿瘤分析中的系统应用支持了我们对肿瘤发生的遗传驱动因素的理解取得了指数级的进展，并揭示了这些疾病的分子复杂性。最近的发现有助于重新定义 T 细胞恶性肿瘤的分类，并提供新的生物标志物来提高诊断准确性和分析对治疗的反应。此外，多种新型靶向治疗方法，包括小分子抑制剂、基于抗体的方法和免疫疗法，在早期临床分析中显示出有希望的结果，有可能彻底改变 T 细胞恶性肿瘤传统治疗方式。
